WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007092416) MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/092416    International Application No.:    PCT/US2007/003099
Publication Date: 16.08.2007 International Filing Date: 06.02.2007
IPC:
C07D 487/04 (2006.01), A61K 31/4985 (2006.01), A61P 3/00 (2006.01)
Applicants: BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Route 206 and ProvinceLine Road, Princeton, New Jersey 08543-4000 (US) (For All Designated States Except US).
ZHAO, Guohua [US/US]; (US) (For US Only)
Inventors: ZHAO, Guohua; (US)
Agent: RODNEY, Burton; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US)
Priority Data:
60/765,530 06.02.2006 US
Title (EN) MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
(FR) ANTAGONISTES DE RECEPTEUR-1 DE L'HORMONE DE CONCENTRATION DE LA MELANINE
Abstract: front page image
(EN)The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula (I) wherein R1a, R1b, R1c, Q, A, R3, W, D and R2 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.
(FR)La présente invention concerne des composés, parmi lesquels tout stéréoisomère, solvate, promédicament et formes pharmaceutiquement acceptables dérivés, selon la Formule (I) où R1a, R1b, R1c, Q, A, R3, W, D et R2 sont définis ici. En outre, la présente application propose des compositions pharmaceutiques contenant au moins un composé selon la Formule I et en option au moins un agent thérapeutique supplémentaire. Finalement, la présente application propose des procédés de traitement d'un patient souffrant d'une maladie modulée MCHR-1 ou d'un trouble tel que par exemple, l'obésité, le diabète, la dépression ou l'anxiété, en administrant une dose effective thérapeutiquement d'un composé respectant la Formule I.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)